Skip to main content
Blau Syndrome and Early-Onset Sarcoidosis: A Six Case Series and Review of the Literature.
Archives of Rheumatology
  • Ayşenur PaÇ Kisaarslan
  • Betül SÖzerİ
  • Nihal Şahİn
  • Sümeyra Özdemİr ÇİÇek
  • Zübeyde GÜndÜz
  • Erkan Demİrkaya
  • Afig Berdelİ
  • Serdal Sadet Özcan
  • Hakan PorazoĞlu
  • Ruhan DÜŞÜnsel
Document Type
Publication Date
URL with Digital Object Identifier

Objectives: This study aims to discuss the clinical, laboratory and genetic findings, and treatment options for six patients who were diagnosed with Blau syndrome (BS)/early-onset sarcoidosis (EOS).

Patients and methods: The study included four patients (2 males,2 females; mean age 7 years; range 4 to 10 years) with EOS and two siblings (1 male, 1 female; mean age 10 years; range, 9 to 11 years) with BS. Age, age of initial symptoms, age of diagnosis; articular involvement, presence of uveitis, dermatitis, or fever, other organ involvement, laboratory findings, results of metabolic tests for mucopolysaccharidosis and mucolipidosis, results of genetic, pathologic, and immunologic tests, radiologic findings to evaluate skeletal dysplasia, and treatment options were collected.

Results: The median age at diagnosis of all patients was 6 years (range, 1 to 10 years). Five patients had camptodactyly and bilateral boggy synovitis in the wrists and ankles, one had granulomatous inflammatory changes in the liver and kidney biopsy, and one had attacks of fever and granulomatous dermatitis. None had uveitis. The detected mutations in nucleotide-binding oligomerization domain containing 2 (NOD2) were P268S (rs2066842), M513T (rs104895473), R702W (rs2066844), V955I (rs5743291), H343Y (rs199858111), and M491L (16:50745293). The treatments of patients included corticosteroids, non-steroid anti-inflammatory drugs, methotrexate, infliximab, adalimumab, anakinra, and canacinumab.

Conclusion: Camptodactyly and boggy synovitis are important signs of BS/EOS. Methotrexate and tumor necrosis factor blockers are more effective in patients with predominantly articular symptoms. In patients 5 and 6 and their mother, we determined a novel M491L mutation in the NOD2 gene. Currently, this work is in progress towards identifying the pathogenesis and treatment options for this disease.

Creative Commons License
Creative Commons Attribution 4.0
Citation Information
Ayşenur PaÇ Kisaarslan, Betül SÖzerİ, Nihal Şahİn, Sümeyra Özdemİr ÇİÇek, et al.. "Blau Syndrome and Early-Onset Sarcoidosis: A Six Case Series and Review of the Literature." Archives of Rheumatology Vol. 35 Iss. 1 (2020) p. 117 - 127
Available at: